Blood Test Detects Brain Tumours with 90% Accuracy

Key Takeaways

• Test identifies two blood proteins linked to glioblastoma
• Achieves 90% accuracy in detecting brain tumors
• Clinical trial spans six UK and four international sites
• Aims to enable GP‑level screening before MRI referral
• Potential NHS rollout within ten years pending approval

Summary

Scientists at the University of Manchester have developed a blood test that detects brain tumours with 90% accuracy by measuring a pair of proteins. The test, validated in glioblastoma patients, is being evaluated in a multi‑site clinical trial across six UK locations and four overseas centres. Researchers envision a simple, Covid‑test‑style device that GPs could use to flag suspicious cases before ordering MRI scans. Regulatory submission is planned, with hopes for NHS adoption within a decade.

Pulse Analysis

The diagnosis of primary brain tumours, particularly aggressive forms like glioblastoma, has long depended on high‑resolution MRI and invasive surgical biopsies. These procedures are expensive, time‑consuming, and carry significant risk, often delaying treatment initiation. A blood‑based biomarker—sometimes called a liquid biopsy—offers a compelling alternative by providing clinicians with rapid, objective data that can be collected in primary‑care settings. By reducing the need for immediate imaging, such a test could streamline patient pathways and alleviate pressure on radiology departments.

The Manchester‑led study pinpointed a duo of circulating proteins that together signal the presence of malignant brain tissue with roughly 90% sensitivity and specificity. Conducted across six UK hospitals and four international sites, the trial not only validates the assay’s performance but also explores its utility in monitoring treatment response during radiotherapy and chemotherapy. Expanding the panel to cover additional tumour subtypes could further broaden its clinical relevance, positioning the test as a versatile tool for oncologists and neuro‑surgeons alike. Importantly, the research underscores the growing convergence of health‑tech innovation and traditional oncology, where data‑driven diagnostics are reshaping therapeutic decision‑making.

If regulatory approval is secured, the test could be deployed as a point‑of‑care device akin to a rapid Covid test, enabling general practitioners to order a simple finger‑prick assay when patients present recurrent headaches. Early risk stratification would trigger timely MRI referrals, potentially catching tumours at more treatable stages and lowering overall healthcare costs. The projected ten‑year horizon for NHS integration reflects both the rigorous validation required and the transformative promise of a non‑invasive, scalable diagnostic. As health systems worldwide grapple with rising cancer incidence, such liquid‑biopsy platforms may become a cornerstone of proactive, precision medicine.